46.31 0.00 (0.00%)
After hours: 4:27PM EDT
|Bid||42.00 x 1200|
|Ask||49.87 x 800|
|Day's Range||45.36 - 46.68|
|52 Week Range||14.56 - 52.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.17|
In the second quarter, PTC Therapeutics generated revenues of $68.7 million—compared to $48.0 million in the second quarter of 2017, which reflected ~43% growth YoY (year-over-year). In the first half of 2018, PTC Therapeutics reported net revenues of $124.8 million—compared to $74.5 million in the first half of 2017.
On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as PTC Therapeutics Inc (NASDAQ:PTCT), with a market cap of US$2.38b, often getRead More...
SOUTH PLAINFIELD, N.J. , Sept. 13, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, ...
SOUTH PLAINFIELD, N.J., Sept. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) is pleased to announce the recipients of the Company's 2018 global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the Duchenne muscular dystrophy community. The impact of the STRIVE Awards will be felt across three different continents, with awards going to patient organizations in Argentina, Brazil, Canada, Croatia, Hungary, Ireland, Slovenia and Turkey.
NEW YORK, NY / ACCESSWIRE / September 7, 2018 / U.S. benchmarks closed mostly lower on Thursday, with the Dow Jones remaining in the green, as internet and tech shares slumped. The Dow Jones Industrial ...
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MACOM ...
SOUTH PLAINFIELD, N.J., Aug. 24, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on August 22, 2018 it approved non-statutory stock options to purchase an aggregate of 381,500 shares of its common stock to 15 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on August 22, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
SOUTH PLAINFIELD, N.J., Aug. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT), today announced that it has successfully completed the acquisition of Agilis Biotherapeutics, Inc., a private biotechnology company focused on the advancement of innovative gene therapy programs for rare genetic disorders that affect the central nervous system (CNS). "We are excited to complete the acquisition and welcome the Agilis employees to PTC," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "We have added a team with exceptional gene therapy experience, a targeted micro-delivery gene therapy platform that has demonstrated durable clinical benefit, as well as gene therapy manufacturing and R&D capabilities.
NEW YORK, NY / ACCESSWIRE / August 15, 2018 / U.S. equities snapped losses on Tuesday, as panic over Turkey’s currency eased and market participants focused on upbeat corporate earnings and strong economic ...
SOUTH PLAINFIELD, N.J., Aug. 10, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on August 6, 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on August 6, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 75.00% and -1.56%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South Plainfield, New Jersey-based company said it had a loss of 21 cents. Losses, adjusted for amortization costs, were 9 cents per share. The biopharmaceutical company posted ...
Entered into agreement to acquire Agilis Biotherapeutics In-licensed LATAM commercial rights to Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) EC approval of Translarna™ label expansion to children ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / PTC Therapeutics, Inc. (NASDAQ: PTCT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. ...
TEGSEDI has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). TEGSEDI is also the subject of a pending new drug application in the U.S. and Canada.
SOUTH PLAINFIELD, N.J. , July 26, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2018 financial ...
Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. The company’s sales and earnings came in ahead of Wall Street estimates. Biogen’s spinal muscular atrophy drug, Spinraza, registered sales of $423 million in Q2 2018, which almost doubled compared to the $203 million sales reported in Q2 2017.
PTC Therapeutics (PTCT) generated revenues of $56.1 million in the first quarter, compared to $26.5 million in the first quarter of 2017. PTC Therapeutics’ Emflaza was launched in May 2017, which has driven the company’s revenue growth.
On July 19, PTC Therapeutics (PTCT) entered into an agreement to acquire Agilis Biotherapeutics. This acquisition is expected to include an upfront payment of $50.0 million in cash and ~$150.0 million in PTC Therapeutics common stock. The acquisition of Agilis Biotherapeutics by PTC Therapeutics is expected to close during the third quarter.
SOUTH PLAINFIELD, N.J., July 24, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the publication of data in Muscle & Nerve comparing the efficacy and safety of deflazacort and prednisone/prednisolone from the placebo arm of the ACT DMD study. The results demonstrated a clinically differentiated benefit of deflazacort over prednisone/prednisolone in slowing disease progression as measured using physical function endpoints and the time to delay loss of ambulation. Duchenne muscular dystrophy patients treated with deflazacort had notably less decline from baseline in 6-minute walk distance at Week 48 than those treated with prednisone/prednisolone.
NEW YORK, NY / ACCESSWIRE / July 20, 2018 / U.S. indexes ended their five day winning streak, which was spurred by strong corporate earnings, as losses from the financial sector dragged markets lower on ...